» Articles » PMID: 38977324

Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development

Overview
Journal Pharmacol Rev
Specialty Pharmacology
Date 2024 Jul 8
PMID 38977324
Authors
Affiliations
Soon will be listed here.
Abstract

Bile acids are the end products of cholesterol catabolism. Hepatic bile acid synthesis accounts for a major fraction of daily cholesterol turnover in humans. Biliary secretion of bile acids generates bile flow and facilitates biliary secretion of lipids, endogenous metabolites, and xenobiotics. In intestine, bile acids facilitate the digestion and absorption of dietary lipids and fat-soluble vitamins. Through activation of nuclear receptors and G protein-coupled receptors and interaction with gut microbiome, bile acids critically regulate host metabolism and innate and adaptive immunity and are involved in the pathogenesis of cholestasis, metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, type-2 diabetes, and inflammatory bowel diseases. Bile acids and their derivatives have been developed as potential therapeutic agents for treating chronic metabolic and inflammatory liver diseases and gastrointestinal disorders. SIGNIFICANCE STATEMENT: Bile acids facilitate biliary cholesterol solubilization and dietary lipid absorption, regulate host metabolism and immunity, and modulate gut microbiome. Targeting bile acid metabolism and signaling holds promise for treating metabolic and inflammatory diseases.

Citing Articles

Cross-talk between macrophages and gut microbiota in inflammatory bowel disease: a dynamic interplay influencing pathogenesis and therapy.

Ning S, Zhang Z, Zhou C, Wang B, Liu Z, Feng B Front Med (Lausanne). 2024; 11:1457218.

PMID: 39355844 PMC: 11443506. DOI: 10.3389/fmed.2024.1457218.

References
1.
Patti M, Houten S, Bianco A, Bernier R, Larsen P, Holst J . Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring). 2009; 17(9):1671-7. PMC: 4683159. DOI: 10.1038/oby.2009.102. View

2.
Gerhard G, Styer A, Wood G, Roesch S, Petrick A, Gabrielsen J . A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013; 36(7):1859-64. PMC: 3687273. DOI: 10.2337/dc12-2255. View

3.
Palmer M, Jennings L, Silberg D, Bliss C, Martin P . A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. BMC Pharmacol Toxicol. 2018; 19(1):10. PMC: 5857122. DOI: 10.1186/s40360-018-0200-y. View

4.
Duboc H, Rajca S, Rainteau D, Benarous D, Maubert M, Quervain E . Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2012; 62(4):531-9. DOI: 10.1136/gutjnl-2012-302578. View

5.
Schreuder T, Marsman H, Lenicek M, van Werven J, Nederveen A, Jansen P . The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2010; 298(3):G440-5. DOI: 10.1152/ajpgi.00322.2009. View